More ASCO Roundup…

• ZymoGenetics (ZGEN) announced positive results from a Phase 2 trial in patients receiving 2nd or 3rd line therapy for advanced renal cell carcinoma with the combination of recombinant IL-21 and Nexavar® (sorafenib). The combo showed an overall response rate (assessed by independent review) of 21% (CR+PR), a disease control rate of 82% (CR+PR+SD), and progression-free survival (PFS) of 5.7 months. [Yahoo!Finance]

• Pfizer (PFE) and Celldex Therapeutics (AVAN) presented updated data on CDX-110 (PF-04948568), an immunotherapeutic vaccine that targets the epidermal growth factor receptor variant III (EGFRvIII) which is currently in a phase 2 brain cancer trial. [Genetic Engineering & Biotechnology News]

• Calistoga Pharmaceuticals’ CAL-101 showed a partial clinical response in 6 out of 12 patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or B-cell non-Hodgkin’s lymphoma (NHL). [BusinessWire]

• ZIOPHARM Oncology (ZIOP) presented positive data from both a Phase Ib clinical trial and preclinical dosing studies of indibulin (ZybulinTM or ZIO-301), the company’s tubulin binding agent. [Yahoo!Finance]

• Genentech presented data on T-DM1, a Herceptin follow up using Immunogen’s (IMGN) DM1 cancer-cell killing agent. The data showed that 25% of patients had a confirmed objective response with 35% of patients demonstrating clinical benefit defined by either a confirmed objective response or stable disease lasting for at least 6 months. [Yahoo!Finance]

• Cytokinetics (CYTK) presented interim data from the Phase I portion of a Phase 1/2 clinical trial data evaluating SB-743921, a novel inhibitor of kinesin spindle protein (KSP), in patients with non-Hodgkin and Hodgkin lymphoma. [Yahoo!Finance]

• Pfizer (PFE) presented three abstracts on results from studies evaluating figitumumab (CP-751,871), the company’s investigational anti-insulin growth factor-type 1 receptor (IGF-1R) antibody in development for non-small cell lung cancer (NSCLC). [Yahoo!Finance]

• Accentia Biopharmaceuticals’ cancer vaccine delayed the return of patients’ lymphoma by more than a year following remission with chemotherapy. [Bloomberg]

• Herceptin extends the lives of gastric cancer patients by almost 3 months in those that are HER-2 positive. [Bloomberg]

• Eli Lilly’s Gemzar slows the spread of cervical cancer. [Bloomberg]

• Telik (TELK) presented data from its ASSIST-5 Phase 3 rtrial of TELCYTA® (canfosfamide) in combination with pegylated liposomal doxorubicin (PLD) vs. PLD alone in second-line therapy in platinum refractory or resistant ovarian cancer. [Yahoo!Finance]

• Keryx Biopharmaceuticals (KERX) presented data from its advanced metastatic colon cancer trial using KRX-0401 (Perifosine). [Yahoo!Finance]

• Finally, Forbes asks if cancer drugs are too expensive. [Forbes]

Anonymous Tip? Comments? Contact us at: hr@iguanabio.com

Related Posts